Abstract
Herceptin (trastuzumab) is an adjuvant chemotherapy agent used in treatment of certain breast cancers. Limited information is available on the use of herceptin in pregnancy. This case is a twin pregnancy exposed to herceptin until 23 weeks' gestation. One twin had chronic renal failure develop, whereas the other twin did not.
MeSH terms
-
Adult
-
Amniotic Fluid / drug effects
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Breast Neoplasms / drug therapy*
-
Carcinoma, Ductal, Breast / drug therapy
-
Chemotherapy, Adjuvant
-
Creatinine / blood
-
Diseases in Twins / chemically induced
-
Fatal Outcome
-
Female
-
Humans
-
Infant, Newborn
-
Kidney Failure, Chronic / blood
-
Kidney Failure, Chronic / chemically induced
-
Oligohydramnios / epidemiology*
-
Pregnancy
-
Pregnancy Complications, Neoplastic / drug therapy*
-
Pregnancy Outcome*
-
Pregnancy, Multiple*
-
Prenatal Exposure Delayed Effects / chemically induced
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Creatinine
-
Trastuzumab